• Publications
  • Influence
The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
TLDR
Topical ocular application of AL-4943A effectively inhibits antigen- and histamine-stimulated conjunctivitis in guinea pigs and concentration-dependent inhibited the vascular permeability response, indicating the compound has an acceptable onset and a long duration of action. Expand
Secretion of proinflammatory cytokines by human conjunctival epithelial cells.
TLDR
It is suggested that conjunctival epithelial cells may contribute to the pathogenesis of human ocular diseases by production of proinflammatory cytokines. Expand
Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats.
TLDR
Data suggest that lodoxamide's in vivo anti-allergic activity in the conjunctiva is associated with its ability to prevent allergic mediator release from mast cells contained in this same tissue. Expand
Leflunomide: Inhibition of S-antigen induced autoimmune uveitis in Lewis rats
TLDR
Results suggest that leflunomide may be useful for treating autoimmune diseases of the eye, including rheumatoid arthritis in man. Expand
Promotion of corneal allograft survival with leflunomide.
TLDR
The results indicate that leflunomide holds considerable promise as an antirejection drug for use in recipients of corneal transplants in whom cyclosporin A and steroids are contraindicated. Expand
Changes in ocular mast cell numbers and histamine distribution during experimental autoimmune uveitis.
TLDR
The data confirm that choroidal mast cell numbers decrease with clinical onset of S-antigen-induced EAU in Lewis rats, and establish that the decrease is statistically significant, and show that the mast cell involvement in EAU includes the mast cells of the limbus. Expand
The efficacy of leflunomide in S-antigen-induced autoimmune uveitis
TLDR
Results indicate that leflunomide may be useful in treating ocular autoimmune diseases. Expand
Medicinal composition containing 5-methyl-isoxazole-4-carboxylic acid anilide or 2-hydroxyethylidene-cyanoacetic acid anilide for treating eye disease
PURPOSE: To obtain the subject medicinal composition for treating eye diseases caused by immunological factors. CONSTITUTION: This medicinal composition for treating eye diseases caused byExpand
Anilides acid 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hidroxietilidenciano for treating eye diseases.
DISCOVERED THE USE OF anilides of 5-METILOISOXAZOL-4 RA TREAT EYE DISEASES WITH IMMUNE etiology.